Hims stock clawed higher Wednesday though analysts laid out low expectations for Him & Hers' branded tirzepatide.

Telehealth providers, whose revenue skyrocketed amidst GLP-1 shortages, remain defiant on their compounded semaglutide ...

Eli Lilly (LLY) leads with groundbreaking tirzepatide (Mounjaro/Zepbound), while Hims & Hers Health (HIMS) faces challenges. Find out who is the winner.

Hims & Hers Health (NYSE:HIMS) stock gains as the company adds Eli Lilly's (LLY) weight loss therapy tirzepatide & generic liraglutide to its platform. Read more here.

Zepbound is made by drugmaker Eli Lilly. While Hims & Hers offers it for $1,899 per month, Lilly said the price on its own LillyDirect platform starts at $349 for self-paying customers. With insurance ...

After Hims & Hers (HIMS) announced yesterday that the company is broadening its weight loss offering to include Lilly’s (LLY) branded ...

Telehealth firm Hims & Hers Health said on Tuesday it plans to sell Eli Lilly's weight-loss drug, as it widens its offerings ...

Craig Primack stated in part: “In my experience of treating thousands of people, lasting results come from focusing on the individual, not just the condition. This simple belief has shaped the way ...

Hims & Hers Health Inc (NYSE:HIMS) shares spiked higher in afternoon trading Tuesday after the company said it will offer Eli Lilly And Co's (NYSE:LLY) Zepbound through its Telehealth platform.

Large-scale providers of tirzepatide and semaglutide such as San Francisco-based Hims & Hers are among those whose compounded medications comes from outsourcers. As the restrictions are phased ...

Shares of Hims & Hers closed 5.1% higher after the company said it will expand its weight-loss offerings with branded versions of Lilly's tirzepatide — the active ingredient in weight-loss drug ...